Abstract |
The nitrosourea, fotemustine, was given intravenously in 1 h constant-rate infusion to 66 patients in a multicentric study to assess both fotemustine pharmacokinetic behaviour and the pharmacokinetic-pharmacodynamic relationships. Depending on the tumour type treated, two administration and sampling protocols were used: 100 mg/m2/week as a conventional dose (six samples, 44 patients) and 300-500 mg/m2/day as a high dose (10 samples, 22 patients). The 91 time-concentration curves were best described by either a one-(55) or a two-compartment (36) model, and their mean clearance values did not differ significantly (85.3 +/- 6.5 and 101.3 +/- 9.5 l/h, respectively, P = 0.1727). Fotemustine pharmacokinetics were not influenced by repeated treatment (time-independence) nor by dose level (dose-independence). The pharmacodynamic effect observed on white blood cell count was expressed by a logit regression model involving the area under the curve mainly and the total administered dose. White blood cell toxicity could be predicted as a function of the dose for a given patient with a known fotemustine clearance value.
|
Authors | A Iliadis, M C Launay-Iliadis, C Lucas, R Fety, F Lokiec, B Tranchand, G Milano |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 32A
Issue 3
Pg. 455-60
(Mar 1996)
ISSN: 0959-8049 [Print] England |
PMID | 8814692
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- Organophosphorus Compounds
- fotemustine
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(pharmacokinetics, therapeutic use, toxicity)
- Dose-Response Relationship, Drug
- Female
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Nitrosourea Compounds
(pharmacokinetics, therapeutic use, toxicity)
- Organophosphorus Compounds
(pharmacokinetics, therapeutic use, toxicity)
- Prospective Studies
- Time Factors
|